Recognition of Patentability of Claims

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or the "Company"), the only publicly listed longevity company in Europe, is pleased to announce that its European patent (No. 22808414.1, Publication No. EP4338267) was officially published in the European Patent Office (EPO) Bulletin on 15 October 2025.

The EPO has recognized the patentability of claims of Genflow's Euro-PCT application, marking a major milestone in the Company's ongoing intellectual property strategy. The European publication number EP4630038 appeared in the Bulletin, signifying that the patent application entered its final pre-grant phase under Article 67(3) EPC. However, Genflow will still need to bring the description into compliance with the claims to respond to this Official Letter; only then will the European Patent Office issue the intention to grant.

With publication, provisional protection took effect across participating EPO member states, allowing Genflow to enforce protection following national validation. This status confirmed the formal recognition of Genflow's application and underscored significant progress toward full patent grant and legal protection across Europe.

Strategic Significance

This publication represents a major step toward securing European patent recognition for key elements of Genflow's longevity gene therapy platform. As the patent enters its final stage before formal recognition, Genflow is positioned to benefit from potential EU grant opportunities and stronger leverage in partnership discussions with pharmaceutical and biotech companies. It also underscores the continued progress in securing the intellectual property backbone of Genflow's SIRT6-based technology across Europe.

• Eric Leire, Chief Executive Officer of Genflow Biosciences, commented: "The publication by the EPO represents a major validation of our scientific innovation and long-term IP strategy. Securing formal European recognition for our patent moves us closer to full protection of our longevity gene therapy platform and strengthens our strategic position for future partnerships and funding opportunities."